CLEC12A and acute myeloid leukemia: These nanoparticles were modified to deplete AML cells of GSH and to target the leukaemic cells by conjugation to a peptide that recognises C-type lectin-like molecule-1 (CLL-1), which is overexpressed on AML blasts and stem cells.